Breeze Holdings Acquisition CORP DEF 14A proxy statements
Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.
Breeze Holdings Acquisition Corp. has filed a supplement to its definitive proxy statement to correct an error in the proxy card for its upcoming Special Meeting, requiring shareholders to resubmit votes.
DEFM14A: Breeze Holdings and YD Biopharma to Merge, Creating Nasdaq-Listed Biopharmaceutical Company
Breeze Holdings Acquisition Corp. (BRZH) will merge with YD Biopharma Limited, valuing the combined entity at \$688.3 million, with the resulting company to be listed on The Nasdaq Capital Market under the ticker symbol "YDES".
DEF: Breeze Holdings Seeks Extension for Biopharma Merger Amid Nasdaq Delisting and Liquidation Risks
Breeze Holdings Acquisition Corp. is seeking stockholder approval to extend its business combination deadline until September 26, 2025, to facilitate its proposed merger with Taiwan-based YD Biopharma Limited, following its delisting from Nasdaq.
Breeze Holdings Acquisition Corp. is seeking stockholder approval to extend the deadline for completing a business combination by up to six months, with a special meeting scheduled for December 23, 2024.
Breeze Holdings Acquisition Corp. is seeking stockholder approval to extend the deadline for completing a business combination, primarily to finalize its merger with TV Ammo.